|
|
Article: Physiogenomic study finds genetic clues to side effects from psychotropic drugs.(Side effects)
- Article from:
- Adverse Event Reporting News
- Article date:
- January 16, 2007
CopyrightCOPYRIGHT 2007 Washington Information Source, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Research published in the Jan. 2 online issue of Nature Publishing Group's "Molecular Psychiatry" describes potential DNA markers for risk and protective factors involved in diabetes-related metabolic side effects from treatment with common anti-psychotic drugs.
The study, entitled "Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients," found that a series of unique DNA variations could predict a patient's likelihood for developing pre-diabetic side effects such as weight gain, according to a statement released by Genomas. Researchers used Genomas's PhysioGenomics Technology, a proprietary biomedical platform that analyzes ...